Free Trial

Squarepoint Ops LLC Cuts Stock Position in Evolus, Inc. (NASDAQ:EOLS)

Evolus logo with Medical background

Squarepoint Ops LLC lessened its stake in shares of Evolus, Inc. (NASDAQ:EOLS - Free Report) by 71.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 26,179 shares of the company's stock after selling 64,180 shares during the quarter. Squarepoint Ops LLC's holdings in Evolus were worth $289,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in EOLS. KBC Group NV bought a new stake in shares of Evolus in the 4th quarter worth approximately $49,000. IFP Advisors Inc boosted its position in Evolus by 17,440.7% during the 4th quarter. IFP Advisors Inc now owns 4,736 shares of the company's stock valued at $52,000 after acquiring an additional 4,709 shares in the last quarter. KLP Kapitalforvaltning AS purchased a new position in shares of Evolus during the 4th quarter worth approximately $106,000. Rafferty Asset Management LLC purchased a new position in shares of Evolus during the 4th quarter worth approximately $115,000. Finally, Quantbot Technologies LP bought a new position in shares of Evolus in the 4th quarter worth approximately $118,000. Institutional investors own 90.69% of the company's stock.

Insider Activity

In other Evolus news, CMO Tomoko Yamagishi-Dressler sold 4,536 shares of the business's stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $13.26, for a total value of $60,147.36. Following the completion of the transaction, the chief marketing officer now directly owns 95,671 shares of the company's stock, valued at approximately $1,268,597.46. The trade was a 4.53% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Rui Avelar sold 27,904 shares of the company's stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $13.26, for a total transaction of $370,007.04. Following the transaction, the insider now owns 362,467 shares of the company's stock, valued at $4,806,312.42. This represents a 7.15% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 86,241 shares of company stock worth $1,048,666. Corporate insiders own 5.90% of the company's stock.

Evolus Trading Up 2.3%

Shares of Evolus stock traded up $0.22 on Tuesday, reaching $9.87. The company had a trading volume of 953,439 shares, compared to its average volume of 731,295. The firm has a market cap of $636.38 million, a price-to-earnings ratio of -10.85 and a beta of 1.00. The company has a debt-to-equity ratio of 20.58, a current ratio of 2.47 and a quick ratio of 2.23. The firm's 50-day moving average price is $10.31 and its two-hundred day moving average price is $11.85. Evolus, Inc. has a 1 year low of $8.67 and a 1 year high of $17.82.

Analyst Ratings Changes

Several brokerages recently weighed in on EOLS. BTIG Research initiated coverage on Evolus in a research note on Thursday, April 17th. They issued a "buy" rating and a $21.00 price target on the stock. HC Wainwright restated a "buy" rating and set a $27.00 target price on shares of Evolus in a report on Thursday, April 10th. Barclays increased their price target on shares of Evolus from $22.00 to $25.00 and gave the stock an "overweight" rating in a research note on Wednesday, March 5th. Finally, Needham & Company LLC reissued a "buy" rating and issued a $22.00 target price on shares of Evolus in a report on Thursday, May 8th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Evolus currently has an average rating of "Buy" and an average target price of $23.75.

View Our Latest Stock Report on EOLS

About Evolus

(Free Report)

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.

See Also

Institutional Ownership by Quarter for Evolus (NASDAQ:EOLS)

Should You Invest $1,000 in Evolus Right Now?

Before you consider Evolus, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evolus wasn't on the list.

While Evolus currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Cheap Growth Stocks Set to Explode This Summer
The Next NVIDIA? Quantum Computing Stocks Set for Explosive Growth
5 Stocks to BUY NOW in July 2025

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines